Ranolazine-d3

• Description:

  Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) [1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

• UNSPSC:

  12352005

• Target:

  Calcium Channel; Sodium Channel

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Field of Research:

  Cardiovascular Disease; Cancer

• Purity:

  99.49

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  CC(C=CC=C1C)=C1NC(CN(CC2)CCN2CC(O)COC3=C(C=CC=C3)OC([2H])([2H])[2H])=O

• Molecular Formula:

  C24H30D3N3O4

• Molecular Weight:

  430.56

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73 (1) :55-73.|[3]Wang WQ, et al. Antitorsadogenic effects of ({+/-}) -N- (2,6-dimethyl-phenyl) - (4[2-hydroxy-3- (2-methoxyphenoxy) propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325 (3) :875-81.|[4]Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418 (1-2) :105-10.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1054624-77-9]